DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland , Portugal, Sweden, and Switzerland). We report the prevalence of the disease for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HD forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the followingHD subpopulations:
Diagnosed Prevalent Cases of Manifest Huntington's Disease per 100,000 People of All Ages in 2019 and 2039
Patient-Flow Diagram for Huntington's Disease in All Countries Under Study in 2019
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Manifest Huntington's Disease over the Next 20 Years
Diagnosed Population at Risk for Huntington's Disease
Diagnosed Incident Cases of Manifest Huntington's Disease
Diagnosed Prevalent Cases of Huntington's Disease
Diagnosed Prevalence of Huntington's Disease by Manifest Status
Diagnosed Prevalent Cases of Manifest Huntington's Disease by Stage
Drug-Treated Cases of Huntington's Disease
Studies Included in the Analysis of Huntington's Disease
Studies Excluded from the Analysis of Huntington's Disease
Risk/Protective Factors for Huntington's Disease
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.